Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
PAT Slowly Yielding to Broader QbD
Experts Now View Process Analytic Technology as a Critical Component of Quality-by-Design
- Nearly eight years after the U.S. FDA’s landmark guidance on process analytic technology (PAT), implementation remains slow and uneven, leading some to ask when this initiative will achieve the broad improvements originally promised. After an initial flurry of articles from major drug firms, and countless conferences devoted to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.